久久综合日本久久综合,亚洲成AV人片在线观看天堂无码,国产在线视频不卡一区二区,久久久久看免费高清特色大片

武漢佰樂博生物技術(shù)有限公司
   
     
聯(lián)系熱線
  • 聯(lián)系人:方經(jīng)理
  • 電 話:027-65279366
  • 郵箱:products@biolabreagent.com
  • 地 址:武漢市東湖新技術(shù)開發(fā)區(qū)神墩四路666號(hào)C棟

佰樂博生物代理AntibodySystem,InVivoMAb Anti-Mouse CD198/CCR8 Antibody (Iv0255)體內(nèi)中和抗體,活性抗體

發(fā)表時(shí)間:2024-05-30

佰樂博生物代理AntibodySystem,InVivoMAb Anti-Mouse CD198/CCR8 Antibody (Iv0255)體內(nèi)中和抗體,活性抗體

鏈接:https://www.antibodysystem.com/product/21631.html

名稱:InVivoMAb Anti-Mouse CD198/CCR8 Antibody (Iv0255)體內(nèi)中和抗體,活性抗體

別名:C-C chemokine receptor type 8, C-C CKR-8, CC-CKR-8, CCR-8, CDw198, Ccr8, Cmkbr8, Ter1

貨號(hào):VME85601

宿主:Mouse

適用物種:Mouse

存儲(chǔ)緩沖區(qū):0.01M PBS, pH 7.4.

形式:Liquid

純度:>95%

克?。?/span>Monoclonal

同型:IgG2a, kappa

應(yīng)用:ELISA, Neutralization

內(nèi)毒素水平Please contact with the lab for this information.

UniProtP56484

用途范圍:僅用于科研

儲(chǔ)存:Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

產(chǎn)品購(gòu)買聯(lián)系方式:027-65279366 /18162686757

郵箱:biolab-reagents@atagenix.com

QQ:2663991332

 

參考文獻(xiàn):

CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory. PMID: 35140181

Chemokine Receptor-Targeted Therapies: Special Case for CCR8. PMID: 35158783

Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody. PMID: 36352891

S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells. PMID: 37420296

Blocking CCL8-CCR8-Mediated Early Allograft Inflammation Improves Kidney Transplant Function. PMID: 35973731

CD4(+)CCR8(+) Tregs in ovarian cancer: a potential effector Tregs for immune regulation. PMID: 37950246

Oxamate enhances the efficacy of CAR-T therapy against glioblastoma via suppressing ectonucleotidases and CCR8 lactylation. PMID: 37770937

The impact of CCR8+ regulatory T cells on cytotoxic T cell function in human lung cancer. PMID: 35354899

TGF-beta-induced CCR8 promoted macrophage transdifferentiation into myofibroblast-like cells. PMID: 35377281

CCR8 as a Therapeutic Novel Target: Omics-Integrated Comprehensive Analysis for Systematically Prioritizing Indications. PMID: 38001911

CCR8 Signaling via CCL1 Regulates Responses of Intestinal IFN-gamma Producing Innate Lymphoid CelIs and Protects From Experimental Colitis. PMID: 33613532

CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer. PMID: 32367308

Role of chemokines in the crosstalk between tumor and tumor-associated macrophages. PMID: 36173487

The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies. PMID: 35693763

聯(lián)系方式
手機(jī):18162686757
微信掃一掃
芦溪县| 西青区| 兰溪市| 彭山县| 方正县| 合阳县| 平阳县| 明水县| 泸溪县| 法库县| 巫山县| 瑞丽市| 萍乡市| 五峰| 宁明县| 高雄县| 惠水县| 锡林浩特市| 晋中市| 宣恩县| 榆林市| 温宿县| 靖州| 丽水市| 贵州省| 乌苏市| 曲阜市| 宁安市| 石嘴山市| 通辽市| 襄樊市| 福泉市| 紫云| 双流县| 象州县| 合肥市| 福鼎市| 红河县| 永宁县| 敦化市| 中山市|